Lafora disease

Reviews in Neurological Diseases

Volumn 3, Issue 3, 2006, Pages 131-135

  Madhavan, Deepak ^a   Kuzniecky, Ruben I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EPM2A; Lafora bodies; Lafora disease; NHLRC1; Progressive myoclonic epilepsies; Spike wave discharges

Indexed keywords

ANTICONVULSIVE AGENT; GLUCOSE; PHENYTOIN; PROTEIN; STEROID;

ADULT; CASE REPORT; CELL INCLUSION; CLINICAL FEATURE; DROWSINESS; DRUG TREATMENT FAILURE; ELECTROENCEPHALOGRAPHY; EPILEPTIC AURA; GRAND MAL SEIZURE; HUMAN; LAFORA POLYGLUCOSAN BODY; MALE; MYOCLONUS EPILEPSY; REVIEW; SKIN BIOPSY; SLEEP; SPIKE WAVE; SYMPTOM; TONIC CLONIC SEIZURE; VIDEORECORDING;

ADOLESCENT; ADULT; AGE OF ONSET; ANTICONVULSANTS; ELECTROENCEPHALOGRAPHY; HUMANS; LAFORA DISEASE; MALE;

EID: 33749344505     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Lafora GR. Über das Corkommen amyloider Körperchen im Innern der Ganglienzellen; zugliech Ein zum Studium der amyloiden Substanz im Nervensystem. Virchows Arch. 1911;205:295-303.
2. Lafora GR, Glueck B. Beitrag zur Histogpathologie der myoklonischen Epilepsie. Z Gesamte Neurol Psychiatr. 1911;6:1-14.
3. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol. 2005;4:239-248.
4. Kobayashi K, Iyoda K, Ohsutka Y, et al. Longitudinal clinicoelectrophysiological study of a case of Lafora Disease proven by skin biopsy. Epilepsia. 1990;31:194-201.
5. Minassian BA. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol. 2002;89:199-210.
6. Yen C, Beydoun A, Drury I. Longitudinal EEG studies in a kindred with Lafora disease. Epilepsia. 1991;32:895-899.
7. Ganesh S, Puri R, Singh S, et al. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet. 2006;51:1-8.
8. Ganesh S, Agarwala KL, Ueda K, et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual specificity phosphatase associated with polyribosomes. Hum Mol Genet. 2000;9:2251-2261.
9. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, et al. Laforin, the dual phosphatase responsible for Lafora disease, interacts with R5(PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet. 2003;12:3161-3171.
10. Wang J, Stuckey JA, Wishart MJ, Dixon JE. A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. J Biol Chem. 2002;277:2377-2380.
11. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA. 2005; 102:8501-8506.
12. Chan EM, Omer S, Ahmed M, et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology. 2004;63:565-567.
13. Delgado-Escueta AV, Ganesh S, Yamakawa K. Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet. 2001;106: 129-138.
14. Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early onset cognitive deficit subphenotype. Hum Mol Genet. 2002;11:1263-1271.
15. Ganesh S, Delgado-Escueta AV, Avila MR, et al. Targeted disruption of Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002;11:1251-1262.